ISRCTN98387311 https://doi.org/10.1186/ISRCTN98387311

Radiotherapy for pathological stage Ia and IIa (Upper) Hodgkin's disease

Submission date	Recruitment status	[_] Prospectively registered
01/07/2001	No longer recruiting	[_] Protocol
Registration date	**Overall study status**	[_] Statistical analysis plan
01/07/2001	Completed	[X] Results
Last Edited	**Condition category**	[_] Individual participant data
01/02/2012	Cancer	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr - -

Contact details
UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
HD1-82

Study information

Scientific Title

Study objectives
Not provided at time of registration

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Non randomised trial

Primary study design
Interventional

Secondary study design
Non randomised controlled trial

Study setting(s)
Not specified

Study type(s)
Not Specified

Participant information sheet
Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied
Lymphoma (Hodgkin's)

Interventions
This is a non randomised study, patients are grouped according to site and stage of disease:

1. Group A: Patients with pathological stage Ia (neck), IIa (neck) and Ia (axilla) are assigned to local field radiotherapy. Patients with neck disease receive 30 Gy midline in sixteen fractions over 3 weeks followed by an additional 5 Gy to the site of palpable disease. Patients with axillary disease receive 35 Gy midline in sixteen fractions over 3 weeks.

2. Group B: Patients with pathological stage Ia (supraclavicular), IIa (all sites except neck) are assigned to mantle radiotherapy. Patients receive a dose of 35 Gy mid line in twenty fractions over 4 weeks followed by an additional 6 Gy to the anterior mediastinum.

Intervention Type
Other

Phase

Not Specified

Primary outcome measure
Not provided at time of registration

Secondary outcome measures
Not provided at time of registration

Overall study start date
01/01/1998

Completion date
31/12/2001

Eligibility

Key inclusion criteria
1. Pathological stage Ia and IIa (upper) Hodgkin's disease
2. Aged 15 to 65 years

Participant type(s)
Patient

Age group
Adult

Sex
Not Specified

Target number of participants
Not provided at time of registration

Key exclusion criteria
Patients with mediastinal disease will not in general be eligible for local radiotherapy alone

Date of first enrolment
01/01/1998

Date of final enrolment
31/12/2001

Locations

Countries of recruitment
England

United Kingdom

Study participating centre
UKCCCR Register Co-ordinator
London
United Kingdom
NW1 2DA

Sponsor information

Organisation
Cancer Research UK (CRUK) (UK)

Sponsor details
PO Box 123
Lincoln's Inn Fields
London
United Kingdom
WC2A 3PX
+44 (0)207 317 5186
kate.law@cancer.org.uk

Sponsor type
Charity

Website
http://www.cancer.org.uk

ROR
https://ror.org/054225q67

Funder(s)

Funder type
Charity

Funder Name
Cancer Research UK

Alternative Name(s)
CR_UK, Cancer Research UK - London, CRUK

Funding Body Type
Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location
United Kingdom

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/02/2005		Yes	No